

INTERMOLECULAR INC  
Form 10-Q  
August 04, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 001-35348

Intermolecular, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation or Organization)	20-1616267 (I.R.S. Employer Identification No.)
---	---

3011 N. First Street San Jose, California (Address of Principal Executive Offices)	95134 (Zip Code)
--	---------------------

(408) 582-5700

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Edgar Filing: INTERMOLECULAR INC - Form 10-Q

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Shares outstanding of the registrant's common stock:

Class	Outstanding as of August 1, 2016
Common stock, \$0.001 par value	49,521,028

INTERMOLECULAR, INC.

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2016

TABLE OF CONTENTS

	Page
<u>PART I — FINANCIAL INFORMATION</u>	
Item 1. <u>Financial Statements</u>	3
<u>Condensed Consolidated Balance Sheets (Unaudited)</u>	3
<u>Condensed Consolidated Statements of Operations (Unaudited)</u>	4
<u>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</u>	5
<u>Condensed Consolidated Statements of Cash Flows (Unaudited)</u>	6
<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	7
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	16
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	23
Item 4. <u>Controls and Procedures</u>	23
<u>PART II — OTHER INFORMATION</u>	
Item 1. <u>Legal Proceedings</u>	24
Item 1A. <u>Risk Factors</u>	25
Item 6. <u>Exhibits</u>	26
<u>Signatures</u>	27

## PART I — FINANCIAL INFORMATION

## ITEM 1. FINANCIAL STATEMENTS

## INTERMOLECULAR, INC. AND SUBSIDIARIES

## Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

	June 30, 2016	December 31, 2015
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 16,356	\$ 11,676
Short-term investments	15,526	23,656
Accounts receivable, net of allowance for doubtful accounts of \$0 as of June 30, 2016 and December 31, 2015	4,770	6,114
Prepaid expenses and other current assets	1,235	1,608
Total current assets	37,887	43,054
Long-term investments	2,302	—
Materials inventory	3,365	4,413
Property and equipment, net	14,385	15,735
Intangible assets, net	5,573	5,969
Other assets	514	506
Total assets	\$ 64,026	\$ 69,677
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 786	\$ 848
Accrued liabilities	1,965	2,385
Accrued compensation and employee benefits	2,303	4,416
Deferred revenue	2,457	2,595
Total current liabilities	7,511	10,244
Deferred rent, net of current portion	3,229	3,299
Other long-term liabilities	63	35
Total liabilities	10,803	13,578
Commitments and contingencies (note 5)		
Stockholders' equity:		
Common stock, par value \$0.001 per share—200,000,000 shares authorized; 49,516,028 and 49,092,260 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively		
	50	49
Additional paid-in capital	211,735	208,972
Accumulated other comprehensive income (loss)	5	(24)

Edgar Filing: INTERMOLECULAR INC - Form 10-Q

Accumulated deficit	(158,567)	(152,898 )
Total stockholders' equity	53,223	56,099
Total liabilities and stockholders' equity	\$64,026	\$ 69,677

See accompanying notes to unaudited condensed consolidated financial statements

## INTERMOLECULAR, INC. AND SUBSIDIARIES

## Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

	Three Months Ended		Six Months Ended June 30,	
	June 30, 2016	2015	2016	2015
<b>Revenue:</b>				
Program revenue	\$ 10,052	\$ 7,251	\$ 22,013	\$ 14,349
Licensing and royalty revenue	1,677	3,743	4,234	6,490
Total revenue	11,729	10,994	26,247	20,839
<b>Cost of revenue:</b>				
Cost of program revenue	4,117	4,544	8,853	9,955
Cost of licensing and royalty revenue	15	76	75	152
Total cost of revenue	4,132	4,620	8,928	10,107
Gross profit	7,597	6,374	17,319	10,732
<b>Operating expenses:</b>				
Research and development	6,924	7,160	13,828	13,660
Sales and marketing	2,130	1,587	4,074	2,896
General and administrative	2,669	3,186	5,269	6,596
Total operating expenses	11,723	11,933	23,171	23,152
Loss from operations	(4,126 )	(5,559 )	(5,852 )	(12,420 )
<b>Other income (expense):</b>				
Interest income (expense), net	40	(121 )	72	(255 )
Other income, net	99	2	115	7
Total other income (expense), net	139	(119 )	187	(248 )
Loss before provision for income taxes	(3,987 )	(5,678 )	(5,665 )	(12,668 )
Provision for income taxes	1	2	4	5
Net loss	\$(3,988 )	\$(5,680 )	\$(5,669 )	\$(12,673 )
Net loss per share, basic and diluted	\$(0.08 )	\$(0.12 )	\$(0.11 )	\$(0.27 )
Weighted-average number of shares used in computing net loss per				
share, basic and diluted	49,448,325	47,935,399	49,316,859	47,767,508

## Related Party Transactions

The Condensed Consolidated Statements of Operations include the following related party transactions:

Three Months Ended	Six Months Ended June 30,
--------------------------	------------------------------

Edgar Filing: INTERMOLECULAR INC - Form 10-Q

	June 30,			
	2016	2015	2016	2015
<b>Revenue:</b>				
Program revenue	\$—	\$3	\$267	\$6
Licensing and royalty revenue	306	910	1,020	1,427
Total revenue	\$306	\$913	\$1,287	\$1,433
<b>Cost of Revenue:</b>				
Cost of program revenue	\$—	\$—	\$102	\$—
Cost of licensing and royalty revenue	2	—	25	
Total cost of revenue	\$2	\$—	\$127	\$—

See accompanying notes to unaudited condensed consolidated financial statements

Edgar Filing: INTERMOLECULAR INC - Form 10-Q

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
Net loss	\$(3,988)	\$(5,680)	\$(5,669)	\$(12,673)
Change in unrealized gain (loss) on available-for-sale-				
securities, net of tax	(1 )	(43 )	29	(13 )
Other comprehensive income (loss)	(1 )	(43 )	29	(13 )
Comprehensive loss, net of income tax	\$(3,989)	\$(5,723)	\$(5,640)	\$(12,686)

See accompanying notes to unaudited condensed consolidated financial statements



## INTERMOLECULAR, INC. AND SUBSIDIARIES

## Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Six Months Ended June 30,	
	2016	2015
<b>Cash flows from operating activities:</b>		
Net loss	\$(5,669 )	\$(12,673)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:		
Depreciation, amortization, and accretion	3,823	5,240
Stock-based compensation	2,049	3,643
Gain on disposal of property and equipment	(19 )	—
Changes in operating assets and liabilities:		
Prepaid expenses and other assets	404	(311 )
Materials inventory	426	585
Accounts receivable	1,343	(735 )
Accounts payable	(211 )	144
Accrued and other liabilities	(1,888 )	1,925
Deferred revenue	(137 )	(1,369 )
Related party deferred revenue	—	(415 )
Net cash (used in) provided by operating activities	121	(3,966 )
<b>Cash flows from investing activities:</b>		
Purchase of investments	(13,262)	(31,047)
Redemption of investments	18,916	29,753
Purchase of property and equipment	(1,786 )	(1,299 )
Proceeds from sale of equipment	22	—
Purchased and capitalized intangible assets	(45 )	(435 )
Net cash (used in) provided by investing activities	3,845	(3,028 )
<b>Cash flows from financing activities:</b>		
Payment of debt	—	(1,000 )
Proceeds from exercise of common stock options	714	605
Net cash (used in) provided by financing activities	714	(395 )
Net increase (decrease) in cash and cash equivalents	4,680	(7,389 )
Cash and cash equivalents at beginning of period	11,676	21,765
Cash and cash equivalents at end of period	\$16,356	\$14,376
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	\$—	\$374
Cash paid for income taxes, net of refunds received	\$4	\$1
<b>Noncash investing/operating activities:</b>		
Transfer of property and equipment to materials inventory	\$588	\$531
Transfer of materials inventory to property and equipment	\$1,211	\$1,321

Additions to property, equipment and intangible assets not paid at the end of the		
period	\$316	\$287

See accompanying notes to unaudited condensed consolidated financial statements

INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements of Intermolecular, Inc. and subsidiaries (the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, certain information and disclosures normally included in complete financial statements prepared in accordance with GAAP have been condensed or omitted. The information in this report should be read in conjunction with the Company's audited consolidated financial statements and notes thereto included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the SEC on March 28, 2016. Certain amounts in the prior year's presentations have been reclassified to conform to the current presentation. These reclassifications had no effect on previously reported net income.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position, results of operations and cash flows for the interim periods presented. The operating results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for any other future interim period or full year. The condensed consolidated balance sheet as of December 31, 2015 is derived from the audited consolidated financial statements as of the year then ended.

Use of Estimates

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenue and expenses. Management uses estimates and judgments in determining recognition of revenues, valuations of accounts receivable, inventories, intangible assets, warrants and assumptions used in the calculation of income taxes and stock-based compensation, among others. These estimates and assumptions are based on management's best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, and adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, investments and accounts receivable. The Company's cash, cash equivalents and investments consist of demand deposits, money market accounts, certificates of deposit, corporate bonds and commercial paper maintained with high quality financial institutions. The Company's accounts receivable consist of non-interest bearing balances due from credit-worthy customers.

## Cash, Cash Equivalents and Investments

The Company holds its cash and cash equivalents in checking, money market and investment accounts with high credit quality financial institutions. The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.

Short-term investments consist principally of corporate debt securities and commercial paper. If applicable, the Company considers marketable securities with remaining time to maturity greater than one year and that are expected to be held to maturity to be classified as long-term. The Company considers all other marketable securities to be short-term marketable securities. The short-term marketable securities are classified as current assets because they can be readily converted into securities with a shorter remaining time to maturity or into cash. The Company determines the appropriate classification of its marketable securities at the time of purchase and re-evaluates such designations as of each balance sheet date. All marketable securities and cash equivalents in the portfolio are classified as available-for-sale and are stated at fair value, with all the associated unrealized gains and losses reported as a component of accumulated other comprehensive income (loss). Fair value is based on quoted market rates or direct and indirect observable markets for these investments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. The cost of securities sold and any gains and losses on sales are based on the specific identification method.

The Company reviews its investment portfolio periodically to assess for other-than-temporary impairment in order to determine the classification of the impairment as temporary or other-than-temporary, which involves considerable judgment regarding factors such as the length of the time and the extent to which the market value has been lower than the amortized cost, the nature of underlying assets, and the financial condition, credit rating, market liquidity conditions and near-term prospects of the issuer. If the fair value of a debt security is less than its amortized cost basis at the balance sheet date, an assessment would have to be made as to whether the impairment is other-than-temporary. If the Company considers it more likely than not that it will sell the security before it will recover its amortized cost basis, an other-than-temporary impairment will be considered to have occurred. An other-than-temporary impairment will also be considered to have occurred if the Company does not expect to recover the entire amortized cost basis of the security, even if it does not intend to sell the security. The Company has recognized no other-than-temporary impairments for its marketable securities.

#### Materials Inventory

Materials inventories are stated at the lower of cost or market value, with cost determined on an average cost basis. Materials inventories consist of raw materials in the amount of \$3.4 million and \$4.4 million as of June 30, 2016 and December 31, 2015, respectively. Materials inventory is used to build and as replacement parts for repairs and maintenance on property plant and equipment. Inventory is no longer purchased for resale as in prior years. Materials inventory that are determined to be in excess of the company requirements or are considered obsolete, are recorded as a cost of revenue. The Company recorded inventory impairment charges of \$0.8 million and \$0.2 million for the six months ended June 30, 2016 and 2015, respectively.

#### Impairment of Long-Lived Assets

The Company evaluates its long-lived assets, which consist of property and equipment and intangible assets, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Impairment exists if the carrying amounts of such assets exceed the estimates of future net undiscounted cash flows expected to be generated by such assets. Should impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the estimated fair value of the asset. The Company did not record impairment of property and equipment during the six months ended June 30, 2016 and 2015.

#### Revenue Recognition

The Company derives its revenue from two principal sources: research and development programs and other services, which consist of technology licensing and royalty fees. Product sales have been made historically, but are not a principal source of revenue. Revenue is recognized when all of the following criteria are met:

- Persuasive evidence of an arrangement exists;
- Delivery has occurred or services have been rendered;
- The fee is fixed or determinable; and
- Collectability of the fee is probable.

Persuasive evidence of the arrangement represents a written contract signed by both the Company and the customer, or a customer purchase order. The Company assesses whether a price is fixed or determinable by, among other things, reviewing contractual terms and conditions related to payment terms. The Company assesses collectability based on factors such as the customer's creditworthiness and past collection history, if applicable. If collection is not probable, revenue recognition is deferred until receipt of payment.

Programs and other services - The Company enters into development programs and other research and development service agreements with customers under which the Company conducts research and development activities with customers. The agreements specify minimum levels of research effort required to be performed by the Company. Payments received under the agreements are not refundable if the research effort is not successful. In some contracts,

the Company retains rights to certain elements of technology developed in the course of its performance, which the customer has an option to license in the future under the terms defined in the agreement. Most arrangements with customers have fixed monthly fees and requirements to provide regular reporting of research and development activities performed, and revenue is recognized in a manner consistent with the fixed monthly fee. The Company also generates a portion of its program revenue from certain research and development service contracts delivered over a specific period of time. These contracts require reliable estimation of costs to perform obligations and the overall scope of each engagement. Revenue under project-based contracts for those programs is recognized as services are performed using percentage of completion method of contract accounting based on costs or labor-hours input method, whichever is the most appropriate measure of the progress towards completion of the contract. Losses on the contracts are recognized in the period when they become probable. Revisions in profit

estimates are reflected in the period in which the conditions that require the revisions become known and can be estimated. Payments received prior to performance are deferred and recognized as revenue when earned over future performance periods.

Licensing and royalty revenue - The Company recognizes revenue for licenses to intellectual property when earned pursuant to the terms of the agreements. Time-based license revenue is recognized ratably over the license term. Licensing and royalty revenue that becomes triggered by specific customer actions, such as exercise of a license option or by sales volume, is recognized when it occurs based on royalty reports or other information received from the licensee. Minimum and prepaid royalties and license fees are recognized ratably over the related periods. Revenue on the sale of intellectual property is recognized in full when title transfers if there are no remaining deliverables related to the intellectual property purchase.

Multiple-element arrangements - Certain of the Company's customer arrangements involve the delivery or performance of multiple products, services or licenses. Product sale arrangements include product maintenance and support. Development programs and other research and development services include licenses of technology and may also include sales of products. For multiple-element arrangements that include hardware products containing software essential to the hardware product's functionality, undelivered software elements that relate to the hardware product's essential software, and undelivered non-software services, the Company allocates revenue to all deliverables based on their relative selling prices.

We evaluate each element in a multiple-element arrangement to determine whether it represents a separate unit of accounting. An element constitutes a separate unit of accounting when it has standalone value and delivery of an undelivered element is both probable and within our control. When these criteria are not met, the delivered and undelivered elements are combined and the arrangement fees are allocated to this combined single unit. If the unit separation criteria are met, we account for each element within a multiple-element arrangement separately, whereby the total arrangement fees are allocated to each element based on its relative selling price, which we establish using a selling price hierarchy. We determine the selling price of each element based on its vendor-specific objective evidence (VSOE), if available, third party evidence (TPE), if VSOE is not available, or estimate of selling price (ESP) if neither VSOE nor TPE is available. We do not recognize revenue that is contingent upon the future delivery of products or services or upon future performance obligations. Essential and non-essential software deliverables used in conjunction with products are evaluated as to whether industry specific software accounting guidance applies to the product as well as the related software. In instances where software is considered non-essential to the functionality of the product, only the software portion and post contract support is evaluated under industry specific software accounting guidance. For purposes of classification in the consolidated statements of operations, revenue is allocated between program revenue, product revenue and licensing and royalty revenue based on objective and reliable evidence of fair value for any elements for which it exists or based on the relative stated invoice amount for elements for which objective and reliable evidence of fair value does not exist. In multiple-element arrangements where hardware and software are sold as part of the solution, revenue is allocated to the hardware and software as a group using the relative selling prices of each of the deliverables in the arrangement based upon the aforementioned selling price hierarchy.

Deferred Revenue - Deferred revenue represents amounts collected from customers for which the related revenue has not been recognized, because one or more of the revenue recognition criteria have not been met, net of the associated costs. The current portion of deferred revenue represents the amount that is expected to be recognized as revenue within one year from the balance sheet date. When deferred revenues are recognized as revenues, the associated deferred costs are also recognized as cost of revenues.

#### Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable are recorded at invoiced amounts and unbilled contractually obligated amounts. Trade accounts receivable are presented net of allowances for doubtful accounts, if applicable, and do not bear interest. The allowance for doubtful accounts is based on the Company's assessment of the collectability of its customer accounts.

The Company reviews the allowance by considering certain factors such as historical experience, industry data, credit quality, age of balances and current economic conditions that may affect customers' ability to pay. The company did not have any allowance for doubtful accounts as of June 30, 2016 and December 31, 2015.



## Concentration of Revenue and Accounts Receivable

Significant customers are those that represent more than 10% of the Company's total revenue or accounts receivable. For each significant customer, including related parties, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:

	Revenue				Accounts Receivable			
	Three Months Ended June 30, 2016		Six Months Ended June 30, 2016		As of June 30, 2016		As of December 31, 2015	
Customer A	17%	41 %	22%	41 %	*		48	%
Customer B	10%	11 %	*	12 %	*		*	
Customer C	14%	23 %	15%	18 %	22 %		16	%
Customer D	40%	—	29%	—	55 %		13	%

\* less than 10%

## Stock-Based Compensation

The Company applies the fair value recognition and measurement provisions of ASC 718 Compensation — Stock Compensation. The Company measures and recognizes compensation expense for all stock-based payment awards issued to employees and directors including employee stock options and restricted stock units based on estimated fair values. The Company uses the grant-date fair value of its common stock to determine the fair value of restricted stock units. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. Stock-based compensation cost is recorded net of estimated forfeitures on a straight-line basis over the requisite service period (generally the vesting period).

The Company accounts for stock options issued to nonemployees based on the fair value of the options determined using the Black-Scholes option-pricing model. The fair value of stock options granted to nonemployees is remeasured each reporting period as the stock options vest and the resulting change in value, if any, is recognized in the Company's consolidated statements of operations during the period the related services are rendered.

## Recent Accounting Pronouncements

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for the Company for the fiscal year beginning March 31, 2018, with early adoption permitted under limited circumstances. The Company is currently evaluating the effect the standard will have on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases." ASU 2016-02 requires that lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the effect the standard will have on its consolidated financial statements.

## 2. Fair Value of Financial Instruments

The Company measures and reports its cash equivalents and investments at fair value. The carrying amounts for cash equivalents and investments approximate their fair values due. The following tables set forth the fair value of the Company's cash equivalents and investments by level within the fair value hierarchy (in thousands):

	As of June 30, 2016			
	Fair Value	Level I	Level II	Level III
<b>Assets:</b>				
Money market funds	\$8,846	\$8,846	\$—	\$ —
Corporate debt securities and commercial paper	17,828	—	17,828	—
Total assets measured at fair value	\$26,674	\$8,846	\$17,828	\$ —

Edgar Filing: INTERMOLECULAR INC - Form 10-Q

	As of December 31, 2015			
	Fair Value	Level I	Level II	Level III
<b>Assets:</b>				
Money market funds	\$98	\$ 98	\$—	\$ —
Corporate debt securities and commercial paper	23,656	—	23,656	—
Total assets measured at fair value	\$23,754	\$ 98	\$23,656	\$ —

Investments are classified as “available-for-sale” and are carried at fair value based on quoted markets or other readily available market information. The Company's investment policy requires investments to have a less than twenty four month maturity term and a minimum credit rating of A-. Unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss. Gains and losses are determined using the specific identification method. Cash, cash equivalents, and investments consisted of the following as of June 30, 2016 (in thousands):

	As of June 30, 2016			
	Amortized Cost	Unrealized Gains	Unrealized Losses	Estimated Fair Value
<b>Assets:</b>				
Cash	\$7,510	\$ —	\$ —	\$ 7,510
Money market funds	8,846	—	—	8,846
Corporate debt securities and commercial paper	17,823	5	—	17,828
Total cash, cash equivalents and investments	\$34,179	\$ 5	\$ —	\$ 34,184

As of December 31, 2015, the Company had \$24,000 of unrealized losses.

### 3. Property and Equipment

Property and equipment consist of the following (in thousands):

	As of	
	June 30, 2016	December 31, 2015
Lab equipment and machinery	\$57,495	\$ 55,649
Leasehold improvements	6,227	6,116
Computer equipment and software	4,425	4,263
Furniture and fixtures	219	207
Construction in progress	1,157	1,625
Total property and equipment	69,523	67,860
Less accumulated depreciation	(55,138)	(52,125)
Property and equipment, net	\$14,385	\$ 15,735

Edgar Filing: INTERMOLECULAR INC - Form 10-Q

The following table presents depreciation expense included in the Condensed Consolidated Statement of Operations and includes amortization of leasehold improvements (in thousands):

	Three Months		Six Months	
	Ended June 30,		Ended June 30,	
	2016	2015	2016	2015
Depreciation expense	\$ 1,587	\$ 1,946	\$ 3,224	\$ 3,990

## 4. Intangible Assets

Intangible assets consist of the following (in thousands):

	As of	
	June 30,	December 31,
	2016	2015
Patents issued	\$6,398	\$ 6,180
Patents pending	768	1,156
Trademarks	40	40
Total intangible assets	7,206	7,376
Less patent amortization	(1,633)	(1,407)
Intangible assets, net	\$5,573	\$ 5,969

Amortization commences upon patent issuance. The useful life of the patents, once issued, will not exceed 20 years, and will depend on the nature of the patent. The average estimated amortization period of the Company's current portfolio is approximately 17 years from the date of patent issuance. The average estimated remaining amortization period of patents acquired from Symyx Technologies, Inc. (Symyx) in 2011 is approximately 3 years.

The following table presents patent amortization expense included in the Condensed Consolidated Statement of Operations (in thousands):

	Three		Six Months	
	Months		Months	
	Ended		Ended	
	June 30,		June 30,	
	2016	2015	2016	2015
Amortization expense	\$117	\$178	\$264	\$363

## 5. Commitments and Contingencies

## Leases

The Company entered into an operating lease agreement in October 2013 that expires in June 2025. Rent expense is being recognized on a straight-line basis over the lease term.

The following table presents rent expense included in the Condensed Consolidated Statement of Operations (in thousands):

	Three	Six Months
	Months	Ended June 30,

	Ended June 30,			
	2016	2015	2016	2015
Rent expense	\$566	\$567	\$1,129	\$1,134

During the second quarter of 2016, the Company made payments of \$0.6 million related to this operating lease.

In December 2015, the Company signed a sublease to lease out a portion of office space. The term of the lease is for 3 years and annual gross rent is approximately \$0.3 million. The sublessee moved in and paid the Company \$0.1 million in rent payment in the second quarter of 2016.

## 6. Stockholders' Equity

### Stock-Based Compensation

The fair value of the employee stock options granted during the period was estimated on the respective grant date using a Black-Scholes option-pricing model with the following weighted-average assumptions:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
Expected term (in years)	5.8	6.0	5.7	5.8
Risk-free interest rate	1.2%	1.5%	1.2%	1.5%
Expected volatility	52%	51%	49%	50%
Expected dividend rate	—%	—%	—%	—%

Edgar Filing: INTERMOLECULAR INC - Form 10-Q

Stock-based compensation expense, net of estimated forfeitures, was included in the following line items on the Condensed Consolidated Statements of Operations (in thousands):

	Three Months		Six Months	
	Ended	Ended	Ended	Ended
	June 30,	June 30,	June 30,	June 30,
	2016	2015	2016	2015
Cost of revenue	\$ 101	\$ 312	\$ 306	\$ 784
Research and development	207	511	536	1,018
Sales and marketing	247	312	390	523
General and administrative	373	612	817	1,318
Total stock-based compensation	\$ 928	\$ 1,747	\$ 2,049	\$ 3,643

The following table presents stock-based compensation expense, net of estimated forfeitures, by grant type (in thousands):

	Three Months		Six Months	
	Ended	Ended	Ended	Ended
	June 30,	June 30,	June 30,	June 30,
	2016	2015	2016	2015
Stock options	\$ 881	\$ 1,124	\$ 1,747	\$ 2,461
Restricted stock awards and restricted stock units (RSUs)	47	623	302	1,182
Total stock-based compensation	\$ 928	\$ 1,747	\$ 2,049	\$ 3,643

The following table presents unrecognized compensation expense, net of estimated forfeitures, related to the Company's equity compensation plans as of June 30, 2016, which is expected to be recognized over the following weighted-average periods (in thousands, except for weighted-average period):

	Unrecognized	Weighted-
	Compensation	Average Period
	Expense	(in years)
Stock options	\$ 5,021	2.5
RSUs	\$ 576	1.6

The following table presents details on grants made by the Company for the following periods:

Six Months Ended	Six Months Ended
June 30, 2016	June 30, 2015
Weighted-	Weighted-
Average Grant	Average Grant

Edgar Filing: INTERMOLECULAR INC - Form 10-Q

	Shares Granted	Date	Fair Value	Shares Granted	Date	Fair Value
Stock options	464,000	\$	0.94	2,686,763	\$	0.82
RSUs	—	\$	—	40,000	\$	1.66

The total intrinsic value of stock options exercised during the six months ended June 30, 2016 and 2015 was \$0.2 million and \$0.7 million, respectively.

RSUs that vested during the six months ended June 30, 2016 and 2015 had fair values of \$0.2 million and \$2.8 million, respectively, as of the vesting date.

### Common Stock

As of June 30, 2016 and December 31, 2015, the Company had reserved shares of common stock for issuance as follows:

	As of June 30, 2016	As of December 31, 2015
Number of stock options outstanding	11,097,337	11,312,218
Number of RSUs outstanding	208,149	258,878
Shares available for future grant	4,435,819	2,960,442
Total shares reserved	15,741,305	14,531,538



## 7. Net Loss per Share

The following table sets forth the computation of the Company's basic and diluted net loss per share during the three and six months ended June 30, 2016 and 2015 (in thousands, except for share and per share amounts):

	Three Months Ended		Six Months Ended June 30,	
	June 30, 2016	2015	2016	2015
Net loss attributable to common stockholders	\$(3,988 )	\$(5,680 )	\$(5,669 )	\$(12,673 )
Shares used in computing net loss per share, basic				
and diluted	49,448,325	47,935,399	49,316,859	47,767,508
Net loss per share, basic and diluted	\$(0.08 )	\$(0.12 )	\$(0.11 )	\$(0.27 )

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:

	Three Months Ended		Six Months Ended	
	June 30, 2016	2015	June 30, 2016	2015
Stock options to purchase common stock	11,097,337	10,928,886	11,097,337	10,928,886
RSUs	208,149	539,410	208,149	539,410
Warrants to purchase common stock	—	90,000	—	90,000

## 8. Income Taxes

The Company follows FASB ASC 740, Income Taxes, for the computation and presentation of its tax provision.

Income tax expense for the six months ended June 30, 2016 was \$4 thousand or -0.07%, on a pretax loss of \$5.7 million. The difference between the Company's effective tax rate and the federal statutory rate of 35% is primarily attributable to the differential in foreign taxes, nondeductible stock-based compensation expense, other currently nondeductible items and movement in its valuation allowance. As of June 30, 2016, the Company maintained a valuation allowance against all of its deferred tax assets. The Company intends to maintain a full valuation allowance until sufficient positive evidence exists to support its reduction.

## 9. Related Party Transactions

As of March 31, 2016, the Company had a related party relationship with a company due to an independent board member serving on both companies' boards of directors and retaining a significant beneficiary ownership stake in the

Company. In May 2016, this related party was acquired by and fully merged into another company. As a result, the acquiree's board of directors was fully dissolved; consequently the Company no longer considers the acquired company a related party as of June 30, 2016.

In November 2006, the Company entered into an Alliance Agreement with a related party that was a beneficial owner of less than 5% of the Company's common stock as of June 2016. The other party and the Company each have an independent board member that serves on both companies' boards of directors. Since November 2006, the agreement has been amended numerous times with the last amendment signed in December 2013.

As of June 30, 2016 and December 31, 2015, the Company had no accounts receivable and deferred revenue balance in either period with respect to its related party relationships. The following table presents related party revenue included in the Condensed Consolidated Statement of Operations from the amended agreement (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
Related party revenue	\$306	\$913	\$1,287	\$1,433
Related party cost of revenue	\$2	\$—	\$127	\$—

At the annual stockholder meeting in May 2016, a new member was elected to the board of directors of the Company. This independent board member is a managing partner of an investment firm which holds a significant ownership position of the Company. As of June 30, 2016, the investment firm was a beneficial owner of approximately 23% of the Company's common stock. The Company had an accrued, unpaid director fees expense of \$4 thousand to the investment firm as of June 30, 2016.

## 10. Information about Geographic Areas

## Revenue

Revenue by geography is based on the billing address of the customer. The following table sets forth revenue by geographic area (in thousands):

	Three Months		Six Months Ended	
	Ended June 30,		June 30,	
	2016	2015	2016	2015
United States	\$4,873	\$7,519	\$13,360	\$14,629
Japan	—	313	313	1,295
Asia-Pacific other	6,286	2,917	11,973	4,484
Europe and Middle East	570	245	601	431
Total	\$11,729	\$10,994	\$26,247	\$20,839

## Long-Lived Assets

Substantially all of the Company's long-lived assets are located in the U.S. An insignificant amount of long-lived assets reside in the Company's foreign subsidiaries and branches in Hong Kong, Japan and Taiwan.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the accompanying consolidated condensed financial statements and notes to assist readers in understanding our results of operations, financial condition and cash flows. Our MD&A is organized as follows:

- Overview. Discussion of our business and overall analysis of financial and other highlights affecting our company in order to provide context for the remainder of MD&A.
- Strategy. Our overall strategy.
- Basis of Presentation. A summary of the primary elements of our financial results.
- Critical Accounting Estimates. Accounting estimates that we believe are most important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.
- Results of Operations. An analysis of our financial results comparing the three and six months ended June 30, 2016 to the three and six months ended June 30, 2015.
- Liquidity and Capital Resources. An analysis of changes in our balance sheets and cash flows, and discussion of our financial condition and sources of liquidity.

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q (Form 10-Q) and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for our fiscal year ended December 31, 2015 (2015 Form 10-K), as filed with the Securities and Exchange Commission. This Form 10-Q contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often identified by the use of words such as, but not limited to, "may," "will," "expect," "believe," "anticipate," "intend," "could," "should," "estimate," or "continue," and similar or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled "Risk Factors" in Part II, Item 1A of this Form 10-Q and in our 2015 Form 10-K. Furthermore, such forward-looking statements speak only as of the date of this Form 10-Q. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

### Overview

We are a partner for the innovation of advanced materials using high throughput experimentation. Advanced materials are critical to sustaining and advancing many industries, including the semiconductor, consumer electronics, aerospace and automotive industries. Using traditional experimental techniques, it can take many years to discover new advanced materials and many more years to deploy them in the marketplace. By leveraging our proprietary high productivity combinatorial (HPC<sup>TM</sup>) platform and multi-disciplinary development team, we strive to enable our customers to more rapidly discover advanced materials and tailor them to suit their needs.

We were founded in 2004 and are headquartered in San Jose, California. Our total revenue increased to \$11.7 million and \$26.2 million for the three and six months ended June 30, 2016 from \$11.0 million and \$20.8 million for the three and six months ended June 30, 2015. Our net loss decreased to \$4.0 million and \$5.7 million for the three months and six months ended June 30, 2016 from a net loss of \$5.7 million and \$12.7 million for the three and six months ended June 30, 2015. Since inception, we have incurred net losses leading to an accumulated deficit of \$158.6 million as of

June 30, 2016.

### Strategy

We currently target large markets that rely on advanced materials for differentiation. Within these broad markets, we target customers that have track records of technological innovation, have significant materials-based research and development (R&D), and are pursuing technical advancements that are critical to their success and strategy.

Generally, our approach is most relevant to industries that rely heavily upon advanced thin film materials such as those achieved using physical vapor deposition (PVD) and atomic layer deposition (ALD) processing tools; however, our approach is also relevant to discovering and understanding advanced

16

---

materials more broadly, including advanced bulk materials such as metal alloys. Historically, we have partnered most extensively in the semiconductor industry and particularly in the area of semiconductor memory such as dynamic RAM (DRAM) and new non-volatile memory (NVM) technologies. Going forward, we currently plan to continue growing our footprint within semiconductors, including partnering in logic, while expanding our engagements in areas such as architectural glass, display, consumer electronics, aerospace and automotive.

#### Basis of Presentation

#### How We Generate Revenue

Our customer engagement process primarily generates revenue in two ways: program revenue; and licensing and royalty revenue. Programs are our primary engagement model with customers and are structured to result in program fees, and in some cases licensing and/or royalty revenue arrangements.

- Program revenue. Program revenue may include payments for research services, milestone payments, and subscription payments for dedicated and shared workflow tools used in the programs and reimbursed payments for consumables and outside services from third parties. Individual programs typically range from six months up to three years. We recognize program revenue in a manner consistent with activities performed. As we engage new customers and negotiate extensions for existing customer agreements that are nearing completion, we expect program revenue to continue to fluctuate.
- Licensing and royalty revenue. Licensing and royalty revenue consists of licensing fees and royalties for granting our customers rights to our proprietary technology and intellectual property (IP). Specifically, this includes licensing the HPC capabilities of our workflows, licensing our informatics and analysis software, and licensing fees and royalties on products commercialized by our customers that incorporate technology developed through our programs. In certain instances, minimum license fees and royalties may be guaranteed by customer contracts and are recognized as revenue ratably over the related periods. We anticipate our licensing and royalty revenue to continue to fluctuate based on the timing and amount of minimum license fees guaranteed by certain customer contracts and the timing of customer reported volume-based royalties.

#### Cost of Revenue

Our cost of revenue is variable and depends on the product mix and type of revenue earned in each period relating to our customer programs.

- Cost of program revenue. Our cost of program revenue primarily consists of salaries and other personnel-related expenses, including stock-based compensation, for our research and development scientists, engineers and development fab process operations employees. Additionally, our cost of revenue includes costs of wafers, targets, materials, program-related supplies, third-party professional fees and depreciation of equipment used in programs. We include inventory obsolescence and customer related asset impairments in cost of program revenue.
- Cost of licensing and royalty revenue. Our cost of licensing and royalty revenue has been, and we expect will continue to be, primarily comprised of the amortization of acquired patents, which were acquired as part of our Symyx asset purchase in November 2011, and licensing obligations.

#### Research and Development

Our R&D expenses consist of costs incurred for development and continuous improvement of our HPC platform, expansion of software capabilities and application research and development that are not associated with customer programs. R&D costs include personnel-related expenses, including stock-based compensation expenses, for our technical staff as well as consultant costs, parts and prototypes, wafers, chemicals, supply costs, facilities costs, utilities costs related to laboratories and offices occupied by technical staff, depreciation on equipment used by technical staff, and outside services, such as machining and third-party R&D costs. We recognize R&D overhead costs that are not allocated to a customer program as expenses within R&D. We expect our R&D expense to increase

modestly in absolute dollars in the near-term periods as resources are reallocated from customer programs to R&D and as we continue to develop and improve our HPC platform and extend the applicability of our platform to a broader set of applications within the industries we serve.

#### Sales and Marketing

Our sales and marketing expenses consist primarily of personnel-related costs, including stock-based compensation, for our sales and marketing employees, as well as payments of commissions to our sales employees, facility costs and professional expenses.

17

---

Professional expenses consist of external website and marketing communication consulting costs and market research. We expect sales and marketing expense to increase in the near-term periods as we develop new business opportunities.

#### General and Administrative

General and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, as well as professional services and facilities costs related to our executive, finance, legal, human resources, management information systems and information technology functions. Professional services consist of outside accounting, information technology, consulting and legal costs. We also incur significant accounting and legal costs related to compliance with rules and regulations enacted by the Securities and Exchange Commission, including the costs of maintaining compliance with Section 404 of the Sarbanes-Oxley Act, as well as insurance, investor relations and other costs associated with being a public company. We expect that general and administrative expense will increase modestly in the near-term periods.

#### Interest income (expense), net

Interest expense consists primarily of interest accrued on our credit facility with Silicon Valley Bank (SVB), which was converted in November 2013 to a three year note and repaid in full in August 2015. Interest income represents interest earned on our cash, cash equivalents and investments. We expect interest income will vary each reporting period depending on our average investment balances during the period and market interest rates.

#### Other Income, net

Other income primarily consisted of sublease income that we receive from subleasing a portion of our office space under a sublease agreement entered into in December 2015. The term of the lease is for three years and annual gross rent is approximately \$0.3 million. The sublessee moved in and occupied the space during the second quarter of 2016.

#### Critical Accounting Estimates

Our consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States and include our accounts and the accounts of our wholly-owned subsidiaries. The preparation of our consolidated financial statements requires our management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosures for contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the applicable periods. Management bases its estimates, assumptions and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances. Different assumptions and judgments would change the estimates used in the preparation of our consolidated financial statements which, in turn, could change the results from those reported. Our management evaluates its estimates, assumptions and judgments on an ongoing basis.

There have been no material changes in the matters for which we make critical accounting estimates in the preparation of our condensed consolidated financial statements during the three and six months ended June 30, 2016 as compared to those disclosed in our 2015 Form 10-K. For further information on our critical and other significant accounting policies, see our 2015 Form 10-K.

#### Recent Accounting Pronouncements

See Note 1 of the Notes to Condensed Consolidated Financial Statements included in this Form 10-Q for recent accounting pronouncements that could have an effect on us.





## Results of Operations

## Comparison of the Three and Six Months Ended June 30, 2016 and 2015

	Three Months Ended June 30,				Six Months Ended June 30,				
	2016	2015	\$ Change	% Change	2016	2015	\$ Change	% Change	
	(in thousands)				(in thousands)				
<b>Revenue:</b>									
Program revenue	\$10,052	\$7,251	\$2,801	39 %	\$22,013	\$14,349	\$7,664	53 %	
<b>Licensing and royalty</b>									
revenue	1,677	3,743	(2,066)	-55 %	4,234	6,490	(2,256)	-35 %	
Total revenue	11,729	10,994	735	7 %	26,247	20,839	5,408	26 %	
Cost of revenue:	4,132	4,620	(488)	-11 %	8,928	10,107	(1,179)	-12 %	
Gross profit	7,597	6,374	1,223	19 %	17,319	10,732	6,587	61 %	
<b>Operating expenses:</b>									
Research and development	6,924	7,160	(236)	-3 %	13,828	13,660	168	1 %	
Sales and marketing	2,130	1,587	543	34 %	4,074	2,896	1,178	41 %	
General and administrative	2,669	3,186	(517)	-16 %	5,269	6,596	(1,327)	-20 %	
Total operating expenses	11,723	11,933	(210)	-2 %	23,171	23,152	19	0 %	
Loss from operations	(4,126)	(5,559)	1,433		(5,852)	(12,420)	6,568		
<b>Other income (expense):</b>									
<b>Interest income (expense),</b>									
net	40	(121)	161		72	(255)	327		
Other income, net	99	2	97		115	7	108		
Total other income									
(expense), net	139	(119)	258		187	(248)	435		
<b>Loss before provision for</b>									
income taxes	(3,987)	(5,678)	1,691		(5,665)	(12,668)	7,003		
Provision for income taxes	1	2	(1)		4	5	(1)		
Net loss	\$(3,988)	\$(5,680)	\$1,692		\$(5,669)	\$(12,673)	\$7,004		

## Revenue

Our revenue increased by 7% during the three months ended June 30, 2016, as compared to the three months ended June 30, 2015, due to a 39% increase in program revenue partially offset by a 55% reduction in licensing and royalty revenue. The increase in program revenue was primarily a result of a \$5.8 million increase in revenue from new customer engagements and \$0.4 million in current customer growth, which was partially offset by a \$3.4 million decrease in revenue related to scheduled completion and reduction of program agreements. The decrease in licensing and royalty revenue was attributable to lower end-market sales and the ending of an exclusivity agreement.

Our revenue increased by 26% during the six months ended June 30, 2016, as compared to the six months ended June 30, 2015, due to a 53% increase in program revenue partially offset by a 35% reduction in licensing and royalty

revenue. The increase in program revenue was primarily a result of an \$11.1 million increase in revenue from new customer engagements and \$0.5 million in current customer growth, which was partially offset by a \$3.9 million decrease in revenue related to scheduled completion and reduction of program agreements. The decrease in licensing and royalty revenue was attributable to lower end-market sales and the ending of an exclusivity agreement.

We expect our revenue to fluctuate from period to period based on demand for, and our resources to fulfill, our services, project completion schedules and end-market sales.

## Edgar Filing: INTERMOLECULAR INC - Form 10-Q

The following table presents revenue by geographic region, based on invoiced locations, during the three and six months ended June 30, 2016 and 2015 in dollars (in thousands) and as a percentage of revenue for the periods presented:

	Three Months Ended June 30,				Six Months Ended June 30,				
	2016		2015		2016		2015		
		% of		% of		% of		% of	
	Revenues	Revenues	Revenues	Revenues	Revenues	Revenues	Revenues	Revenues	
United States	\$4,873	41	% \$7,519	68	% \$13,360	51	% \$14,629	70	%
Japan	—	—	313	3	% 313	1	% 1,295	6	%
APAC other	6,286	54	% 2,917	27	% 11,973	46	% 4,484	22	%
Europe and Middle East	570	5	% 245	2	% 601	2	% 431	2	%
Total	\$11,729	100	% \$10,994	100	% \$26,247	100	% \$20,839	100	%

### Cost of Revenue

Cost of revenue decreased by 11% and 12% during the three months and six months ended June 30, 2016, as compared to the same periods ended June 30, 2015, due to decreases in labor and personnel-related expenses, materials and other costs associated with programs. Stock-based compensation, which was included in personnel-related expenses, decreased by \$0.2 million and \$0.5 million for the three months and six months ended June 30, 2016, compared to the three months and six months ended June 30, 2015.

### Gross Margin

Our gross profit as a percentage of net revenues, or gross margin, has been and will continue to be affected by a variety of factors, including the mix of program revenue and licensing and royalty revenue recognized during the period. We achieve a higher gross margin on licensing and royalty revenue as compared to program revenue.

Gross margin was 65% and 66% during the three months and six months ended June 30, 2016, compared to 58% and 51% for the three and six months ended June 30, 2015. These increases were primarily attributable to our increased revenue and decreased labor and personnel-related expenses, materials and other costs associated with programs during each period.

### Research and Development

R&D expenses decreased by 3% during the three months ended June 30, 2016, as compared to the three months ended June 30, 2015. The change was primarily attributable to reductions in employees, consultant related and facilities costs, partially offset by increases in tool repairs and R&D lab expenses.

R&D expenses increased by 1% during the six months ended June 30, 2016, as compared to the six months ended June 30, 2015. The change was primarily attributable to increases in tool repairs and R&D lab expenses more than offsetting reductions in employees and consultant related costs.

Stock-based compensation, which was included in personnel-related expenses, decreased by \$0.3 million and \$0.5 million for the three months and six months ended June 30, 2016, respectively, compared to the three months and six months ended June 30, 2015.

### Sales and Marketing

Sales and marketing expenses increased by 34% and 41% during the three months and six months ended June 30, 2016, respectively, compared to the three months and six months ended June 30, 2015. The increases were attributable to higher personnel costs related to increased headcount, wages and other related benefits as well as new corporate marketing initiatives.

Stock-based compensation, which was included in personnel-related expenses, increased by \$0.1 million and \$0.1 million for the three months and six months ended June 30, 2016, respectively, compared to the three months and six months ended June 30, 2015.

### General and Administrative

General and administrative expenses decreased by 16% and 20% during the three months and six months ended June 30, 2016, as compared to the three months and six months ended June 30, 2015. The decreases were primarily attributable to lower personnel costs related to decreased headcount, wages, other related benefits and professional fees.

Stock-based compensation, which was included in personnel-related expenses, decreased by \$0.2 million and \$0.5 million for the three months and six months ended June 30, 2016, respectively, compared to the three months and six months ended June 30, 2015.

#### Loss from Operations

Our operating loss decreased by \$1.4 million during the three months ended June 30, 2016, compared to the three months ended June 30, 2015, driven by increased revenue and reduced expenses. Total operating expenses decreased by \$0.2 million during the three months ended June 30, 2016, compared to the three months ended June 30, 2015.

Our operating loss decreased by \$6.6 million during the six months ended June 30, 2016, compared to the six months ended June 30, 2015, driven by increased revenue and reduced expenses. Total operating expenses remained relatively flat during the six months ended June 30, 2016, compared to the six months ended June 30, 2015.

#### Interest Income (Expense), net

The increases in interest income (or decreases in interest expense) during the three months and six months ended June 30, 2016, compared to the three and six months ended June 30, 2015 were related to the interest payments on the SVB loan facility which was fully paid off in the third quarter of 2015. During the three months and six months ended June 30, 2015, the expense primarily consisted of interest expense associated with the Loan Agreement with SVB.

#### Other Income, net

Other Income, net, for the three and six months ended June 30, 2016 consisted principally of sublease income that we recorded from subleasing a portion of our office space under an agreement entered into in December 2015. The sublessee moved in and occupied the space during the second quarter of 2016. Other income (expense), net, during the six months ended June 30, 2015 was not significant.

#### Provision for Income Taxes

Provision for Income Taxes during the three and six months ended June 30, 2016 and 2015 consisted of income taxes on our foreign entities and were not significant during these periods.

#### Net Loss

Our net loss decreased by \$1.7 million during the three months ended June 30, 2016, compared to the three months ended June 30, 2015. The difference between operating loss and net loss during the three months ended June 30, 2016 and June 30, 2015 was primarily related to interest expense associated with the Loan Agreement with SVB in the second quarter of 2015 and subleases income in the second quarter of 2016.

Our net loss decreased by \$7.0 million during the six months ended June 30, 2016, compared to the six months ended June 30, 2015. The difference between operating loss and net loss during the six months ended June 30, 2016 and June 30, 2015 was primarily related to interest expense associated with the Loan Agreement with SVB in the first and second quarters of 2015 and subleases income in the second quarter of 2016.

#### Liquidity and Capital Resources

Prior to our initial public offering in November 2011, we substantially satisfied our capital and liquidity needs through private placements of redeemable convertible preferred stock and, to a lesser extent, cash flow from operations. As of June 30, 2016, we had \$34.2 million of cash, cash equivalents and investments and \$30.4 million of net working capital.

To date, we have incurred significant losses. During the three months ended June 30, 2016 and 2015, we incurred net losses of \$4.0 million and \$5.7 million. As of June 30, 2016, our accumulated deficit was \$158.6 million.

We believe that we have the financial resources needed to meet business requirements for the next 12 months. However, our forecast of the period of time through which our financial resources will be adequate to meet business requirements are forward-looking statements and involve risks and uncertainties. Our future capital requirements will depend on many factors, many of which are set forth in greater detail under the caption "Risk Factors," but generally include without limitation our rate of revenue growth, our expansion of our sales and marketing activities and overhead expenses, the timing and extent of our spending to support our R&D

efforts and our ability to expand programs in the semiconductor industry, whether we are successful in obtaining payments from customers, the financial stability of our customers, whether we can enter into additional contracts in our target industries, the progress and scope of R&D projects performed by us and our customers, the effect of any acquisitions of other businesses or technologies that we may make in the future, the filing, prosecution and enforcement of patent claims, how much funding we may need to develop or enhance our solutions or HPC platform and any necessary responses to competitive pressures. To the extent that existing cash, cash equivalents, short-term investments and cash from operations are insufficient to fund our operations, we may need to raise additional funds through public or private equity or debt financing. We may also seek to invest in or acquire complementary businesses, applications or technologies, any of which could also require us to seek additional equity or debt financing. Additional funds may not be available on terms favorable to us or at all. We maintain almost all of our cash and investments in the United States and therefore are not generally subject to restrictions or tax obligations as we access the cash.

### Cash Flows

The following summary of our cash flows for the periods indicated has been derived from our condensed consolidated financial statements included elsewhere in this filing (in thousands):

	Six Months Ended June 30,	
	2016	2015
Net cash (used in) provided by operating activities	\$121	\$(3,966)
Net cash (used in) provided by investing activities	\$3,845	\$(3,028)
Net cash (used in) provided by financing activities	\$714	\$(395)

### Cash Flows from Operating Activities

We generated positive cash flows from operating activities during the six months ended June 30, 2016, as compared to negative cash flows for the six months ended June 30, 2015, primarily due to improved operating results.

Net cash provided by operating activities during the six months ended June 30, 2016 was primarily attributable to our net loss of \$5.7 million, offset by non-cash charges of \$3.8 million for depreciation, amortization, and accretion and \$2.0 million for stock-based compensation.

Net cash used in operating activities during the six months ended June 30, 2015 was primarily attributable to our net loss of \$12.7 million, offset by non-cash charges of \$5.2 million for depreciation, amortization, and accretion and \$3.6 million for stock-based compensation.

We expect that cash flows from operating activities will fluctuate in future periods due to a number of factors, including our operating results, amounts of non-cash charges, the timing of our billings, collections and disbursements.

### Cash Flows from Investing Activities

Our investing activities consist primarily of purchases and maturities of short-term investments and capital expenditures to purchase property and equipment. In the future, we expect we will continue to make modest capital expenditures to support our operations, and to incur costs to protect our investment in our developed technology and IP.



## Edgar Filing: INTERMOLECULAR INC - Form 10-Q

During the six months ended June 30, 2016, cash provided by investing activities was a result of \$5.7 million in the net redemptions of short-term investments, offset by \$2.0 million in capital expenditures.

During the six months ended June 30, 2015, cash used in investing activities was a result of \$1.3 million in the net purchase of short-term investments, \$1.3 million in capital expenditures, and \$0.4 million in capitalized patent and trademark costs.

### Cash Flows from Financing Activities

To date, we have financed our operations primarily with proceeds from the sale of our redeemable convertible preferred stock and proceeds received from our initial public offering.

During the six months ended June 30, 2016, cash provided by financing activities of \$0.7 million was from proceeds from common stock option exercises.

During the six months ended June 30, 2015, cash used in financing activities was primarily related to the scheduled principal payments on our SVB term loan in the amount of \$1.0 million, which was offset by proceeds from common stock option exercises in the amount of \$0.6 million.

#### Contractual Obligations and Commitments

The following summarizes our contractual obligations as of June 30, 2016 (in thousands):

	Total	Payments Due by Period			
		Less Than One Year	1 - 3 Years	3 - 5 Years	More Than 5 Years
Operating lease obligations	\$23,590	\$1,175	\$7,379	\$5,232	\$9,804
Total	\$23,590	\$1,175	\$7,379	\$5,232	\$9,804

Operating lease agreements represent our obligations to make payments under our non-cancelable lease agreement for our facility in San Jose, California. During the six months ended June 30, 2016, we made regular lease payments of \$1.2 million under this operating lease agreement.

#### Off-Balance Sheet Arrangements

As of June 30, 2016, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which are established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and foreign currency exchange rates. We do not hold or issue financial instruments for trading purposes.

#### Interest Rate Sensitivity

The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without exposing us to significant risk of loss. The securities we invest in are subject to market risk and a change in prevailing interest rates may cause the principal amount of our investments to fluctuate. We maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including commercial paper, corporate debt securities and money market funds. As of June 30, 2016, our investments were primarily in commercial paper, corporate notes and bonds and money market funds. If overall interest rates fell 10% for the three months ended June 30, 2016, our interest income would have decreased by an immaterial amount, assuming consistent investment levels.

#### Foreign Currency Exchange Risk

As we expand internationally, our consolidated results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. Our revenue is denominated in U.S. dollars. Our expenses are generally denominated in the currencies in which our operations are located, which is primarily in the United States, with an insignificant portion of expenses incurred in the local currencies of our wholly-owned subsidiaries in Hong Kong and Japan and our wholly-owned branch in Taiwan. The effect of a hypothetical 10% change in foreign currency exchange rates applicable to our business would not have a material impact on our consolidated financial statements. To date, we have not entered into any material foreign currency hedging contracts, although we may do so in the future.

#### ITEM 4. CONTROLS AND PROCEDURES

##### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) under the Securities Exchange Act of 1934 as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact

that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Based on this evaluation and because of the material weaknesses described below, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were not effective as of December 31, 2015 and June 30, 2016.

As described in our annual report on Form 10-K for the year ended December 31, 2015, management determined that the following control deficiencies that constituted material weaknesses in our internal control over financial reporting existed as of December 31, 2015 and June 30, 2016.

**Control Environment and Accounting for Multiple-element and Nonstandard Revenue Arrangements** - We did not maintain an effective control environment as of December 31, 2015 and June 30, 2016. The principle contributing factors included insufficient qualified personnel with appropriate expertise to perform accounting functions necessary to ensure preparation of financial statements in accordance with generally accepted accounting principles, and inadequate policies and procedures to enable the timely preparation of reliable financial statements. The material weakness in the control environment resulted in certain instances of inappropriate accounting decisions and certain instances where we did not design and maintain effective controls related to our accounting and disclosures over revenue, inventory and the statement of cash flows. The deficiencies led to errors in these accounts, which were corrected prior to the issuance of the financial statements. The errors related to the statement of cash flows and inventory were not material but, when aggregated, could have been material. The errors related to revenue were material. Therefore, in addition to the material weakness in control environment, there is a separate, but related, material weakness related to revenue, because we did not design and maintain effective controls over accounting for multiple-element and nonstandard revenue arrangements.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

#### Changes in internal control over financial reporting

We made no changes to our internal control over financial reporting during the quarterly period ended June 30, 2016, except for the continuation of the remedial efforts as described below to address the material weaknesses described above.

#### Remedial Efforts to Address the Material Weaknesses

Following the identification of the material weaknesses as of December 31, 2015, we initiated remediation measures to address the material weakness over insufficient qualified personnel, which included creating and filling a new accounting position and hiring an outside consultant to assist us in reviewing and updating our policies and procedures, as appropriate. Since December 31, 2015, we have continued to improve our training for all of the key positions in the financial reporting and accounting function and our documentation of accounting policies and procedures.

We cannot assure you that we will be able to remediate our existing material weaknesses in a timely manner, if at all, or that in the future, additional material weaknesses will not exist, reoccur or otherwise be discovered, a risk that is significantly increased in light of the complexity of our business. If our efforts to remediate these material weaknesses are not successful or if other deficiencies occur, our ability to accurately and timely report our financial position, results of operations, cash flows or key operating metrics could be impaired, which could result in late filings of our annual and quarterly reports under the Exchange Act, restatements of our consolidated financial statements or other corrective disclosures. Additional impacts could include a decline in our stock price, suspension of trading or delisting of our common stock, or other material adverse effects on our business, reputation, and results of operations, financial condition or liquidity. Furthermore, if we continue to have these existing material weaknesses or other material

weaknesses or significant deficiencies in the future, it could create a perception that our financial results do not fairly state our financial condition or results of operations. Any of the foregoing could have an adverse effect on the value of our stock.

## PART II — OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in legal proceedings and claims arising in the ordinary course of our business, including but not limited to legal proceedings and claims brought by employees or former employees relating to working conditions or other issues. We are not currently a party to any legal proceedings the outcome of which, if determined adversely to us, we believe would individually or in the aggregate have a material adverse effect on our business, operating results, financial condition or cash flows.

ITEM 1A. RISK FACTORS

The risks described in Part I, Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2015, could materially and adversely affect our business, financial condition or future results. These risk factors are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and operating results. The Risk Factors section of our 2015 Annual Report on Form 10-K remains current in all material respects.

25

---

## ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Incorporated by Reference Filed			
		Form	Date	Number	Herewith
2.1	Asset Purchase Agreement by and between Intermolecular, Inc. and Symyx Technologies, Inc. dated as of July 28, 2011. (1)	S-1/A	09/09/11	2.1	
3.1	Amended and Restated Certificate of Incorporation of Intermolecular, Inc.	10-K	03/16/12	3.1	
3.2	Amended and Restated Bylaws of Intermolecular, Inc.	10-K	03/16/12	3.2	
4.1	Specimen Common Stock Certificate.	S-1/A	11/07/11	4.1	
4.2	Warrant to purchase shares of common stock issued to Timane S.a.r.l. dated June 20, 2008.	S-1	07/29/11	4.2	
4.3	Fourth Amended and Restated Investor Rights Agreement dated as of March 4, 2011, by and among Intermolecular, Inc. and certain stockholders named therein, as amended by Amendment No. 1 to Fourth Amended and Restated Investor Rights Agreement dated as of June 14, 2011.	S-1	07/29/11	10.1	
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
101.INS	XBRL Instance Document				X
101.SCH	XBRL Taxonomy Extension Schema Document				X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document				X

(1) All exhibits, schedules and similar attachments to this exhibit have been omitted. Copies of such exhibits, schedules and similar attachments will be furnished supplementally to the SEC upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTERMOLECULAR, INC.

(Registrant)

Date: August 4, 2016 By: /s/ C. Richard Neely, Jr.

C. Richard Neely, Jr.

Chief Financial Officer